JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

Search

Pfizer

Closed

SectorHealthcare

24.59 0.04

Overview

Share price change

24h

Current

Min

24.55

Max

24.91

Key metrics

By Trading Economics

Income

2.6B

3B

Sales

-4B

14B

P/E

Sector Avg

17.051

34.393

EPS

0.92

Dividend yield

7.19

Profit margin

21.677

Employees

81,000

EBITDA

2.5B

5.1B

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+16.31% upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

7.19%

2.54%

Next Earnings

28 paź 2025

Next Dividend date

2 wrz 2025

Next Ex Dividend date

7 lis 2025

Market Stats

By TradingEconomics

Market Cap

-12B

134B

Previous open

24.55

Previous close

24.59

News Sentiment

By Acuity

39%

61%

125 / 374 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Bullish Evidence

Pfizer Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

5 sie 2025, 11:34 UTC

Earnings

Pfizer Boosts 2025 Adjusted EPS Outlook Following 2Q Gains

5 sie 2025, 20:44 UTC

Earnings

These Stocks Moved the Most Today: Palantir, Vertex, Hims & Hers, Coinbase, BP, and More -- Barrons.com

5 sie 2025, 18:20 UTC

Earnings

Pfizer Stock Rises as Earnings Smash Expectations. But These Challenges Remain. -- Barrons.com

5 sie 2025, 18:17 UTC

Earnings

These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, Coinbase, BP, and More -- Barrons.com

5 sie 2025, 16:04 UTC

Market Talk

Pfizer's New Tax Rate Helps Boost Adj EPS Outlook -- Market Talk

5 sie 2025, 15:25 UTC

Earnings

Correction to These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, Caterpillar, BP, and More -- Barrons.com

5 sie 2025, 13:56 UTC

Earnings

Pfizer Stock Rises as Earnings Smash Expectations. But These Challenges Remain. -- Barrons.com

5 sie 2025, 11:43 UTC

Earnings

Pfizer Stock Pops as Earnings Smash Expectations. Guidance Hiked in Face of Tariffs. -- Barrons.com

5 sie 2025, 11:27 UTC

Earnings

Update: These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, AMD, BP, and More -- Barrons.com

5 sie 2025, 10:57 UTC

Earnings

Pfizer Stock Pops as Earnings Smash Expectations. Why the Outlook Has Been Hiked. -- Barrons.com

5 sie 2025, 10:55 UTC

Earnings

Update: These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, AMD, BP, and More -- Barrons.com

5 sie 2025, 10:53 UTC

Earnings

Pfizer Boosts 2025 Profit Estimate In A Sign Of 'Confidence' -- MarketWatch

5 sie 2025, 10:51 UTC

Earnings

Pfizer: On Track to Deliver About $7.2B Overall Cost Savings From Cost-Improvement Initiatives b/ End of 2027 >PFE

5 sie 2025, 10:50 UTC

Earnings

Pfizer: Expects to Continue to De-Lever in Prudent Manner to Maintain Balanced Capital-Allocation Strategy >PFE

5 sie 2025, 10:49 UTC

Earnings

Pfizer: Current Financial Guidance Doesn't Anticipate Any Share Repurchases in 2025 >PFE

5 sie 2025, 10:49 UTC

Earnings

Pfizer Now Sees 2025 Effective Tax Rate on Adjusted Income About 13%; Had Seen About 15% >PFE

5 sie 2025, 10:48 UTC

Earnings

Pfizer Cuts Adjusted R&D Expenses View to $10.4-$11.4B From $10.7B-$11.7B >PFE

5 sie 2025, 10:48 UTC

Earnings

Pfizer: Guidance Absorbs Impact of Potential Price Changes This Year Based on Letter Received July 31 From President Trump >PFE

5 sie 2025, 10:47 UTC

Earnings

Pfizer: Guidance Absorbs Impact of Currently Imposed Tariffs From China, Canada, Mexico >PFE

5 sie 2025, 10:46 UTC

Earnings

Pfizer Had Seen 2025 Adjusted EPS $2.80-$3.00 >PFE

5 sie 2025, 10:45 UTC

Earnings

Pfizer Raises 2025 EPS Guidance >PFE

5 sie 2025, 10:45 UTC

Earnings

Pfizer 2Q EPS 51c >PFE

5 sie 2025, 10:45 UTC

Earnings

Pfizer Sees FY Adj EPS $2.90-Adj EPS $3.10 >PFE

5 sie 2025, 10:45 UTC

Earnings

Pfizer 2Q Adj EPS 78c >PFE

5 sie 2025, 10:45 UTC

Earnings

Pfizer 2Q Rev $14.7B >PFE

5 sie 2025, 10:45 UTC

Earnings

Pfizer Sees FY Rev $61B-$64B >PFE

4 sie 2025, 15:26 UTC

Earnings

Pfizer Reports Earnings Soon. The Stock Is Slumping for a Reason. -- Barrons.com

30 lip 2025, 18:36 UTC

Earnings

UPS Stock Joins 7% Yielders in S&P 500. Here's Who Else Is in the Club. -- Barrons.com

9 lip 2025, 09:17 UTC

Hot Stocks

Stocks to Watch Wednesday: Freeport-McMoRan, Glencore, Novo Nordisk -- WSJ

10 cze 2025, 12:18 UTC

Earnings

Why Moderna, Pfizer Stocks Are Shrugging Off RFK Jr.'s Firing of Vaccine Advisors. -- Barrons.com

Peer Comparison

Price change

Pfizer Forecast

Price Target

By TipRanks

16.31% upside

12 Months Forecast

Average 28.59 USD  16.31%

High 33 USD

Low 24 USD

Based on 18 Wall Street analysts offering 12 month price targets forPfizer - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

18 ratings

6

Buy

12

Hold

0

Sell

Technical Score

By Trading Central

22.855 / 23.85Support & Resistance

Short Term

Bullish Evidence

Intermediate Term

Bearish Evidence

Long Term

Bearish Evidence

Sentiment

By Acuity

125 / 374 Ranking in Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Pfizer

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as has strategic clinical collaboration with Acepodia Inc. for the development of antibody-cell conjugation-based cell therapies in autoimmune diseases. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.